ExploreDaily DealsShop with an ExpertBuy AgainOrdersHelp & Support
Join NowHealthcare provider? Join Now
logoImage
Log In
  • Medical Supplies
  • Pharmacy
  • IV Therapy
About Us
What Makes Us Different?
Who We Are
Our Core Values
Our Testimonials
Our Culture
How Reliable Are We?
Who We Serve
Providing Cutting Edge Solution Globally
Partner With USA MedPremium
Healthcare Professional Statement
Newsroom
Quality Assurance
Our Service & Solutions
Shop with an Expert
Analytics & Reporting
Inventory Management
Distribution Solutions
Streamline Integration
Cost Effective Healthcare solutions
Supply Chain Optimization
Credit Allocation
Customer Service
Live Chat Support
Contact Us
Shipping & Returns
Terms & Conditions
Order Status
Account
Log In
Forgot Password
Healthcare Provider? Join Now
USA MedPremium
LegitScript Certified
LegitScript CertifiedVerified Healthcare Distributor
Follow us:
©2026 USA MedPremium. All rights reserved.
Privacy
Your Privacy Choices
Cookies Preference
Terms of Use
Site Map
Pharmaceutical Licensing
PrivacyPrivacy
Your Privacy ChoicesYour Privacy Choices
Cookies PreferenceCookies Preference
Terms of UseTerms of Use
Site MapSite Map
Pharmaceutical LicensingPharmaceutical Licensing
  1. Home
  2. All Products
  3. Categories
  4. Rx Prescriptions
  5. Dermatological Agents
  6. Atopic Dermatitis Treatment

Dupixent® Dupilumab 200 mg / 1.14 mL Injection Prefilled Injection Pen 1.14 mL 2 Pens

USAMP#41161286SKU: 00024591902Dupixent®
rxLicense

License Required

productImage

Product Spotlight

  • Store refrigerated at 36° to 46°F (2° to 8°C) in the original carton
  • DUPIXENT is sterile and preservative-free
  • DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids
  • DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma
  • DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • Discard any unused portion